(NASDAQ:SAVA), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to […]

(NASDAQ:PCRX), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NYSE:IIPR), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Innovative Industrial Properties, Inc. (NYSE: IIPR). Shareholders who purchased shares of IIPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required

(NASDAQ:AZN), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

(NASDAQ:MQ), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Marqeta, Inc. (NASDAQ: MQ). Shareholders who purchased shares of MQ during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

(NASDAQ:EPIX), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NasdaqGM:RVNC), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

CEO Bob Jurgensmeier has announced the following officer hire. https://mma.prnewswire.com/media/1098373/Ameritas_Logo.jpg Ameritas CEO Bob Jurgensmeier has named a newly elected officer. Barbara Redstone has been named the new vice president, sales and distribution, retirement plans, with an effective board action date of Jan. 1, 2025. Redstone earned her four-year degree from Louisiana State University and has

(NYSE:CUBI), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Customers Bancorp, Inc. (NYSE: CUBI). Shareholders who purchased shares of CUBI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NASDAQ:MGPI), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of MGP Ingredients, Inc. (NASDAQ: MGPI). Shareholders who purchased shares of MGPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to